Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Cholangiocarcinoma 1

Interventions

Docetaxel 7pembrolizumab 3Trastuzumab 3Radiotherapy 3Paclitaxel 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3Cisplatin 3Vorinostat 2Taxes 2SS1(dsFv)PE38 2Polymerase Chain Reaction 2Magnetic Resonance Spectroscopy 2Immunohistochemistry 2Gene Expression Profiling 2Filgrastim 2Cetuximab 2Biopsy 2zanidatamab 1vandetanib 1trastuzumab deruxtecan 1tipifarnib 1tanespimycin 1talactoferrin alfa 1spartalizumab 1sargramostim 1pertuzumab 1neratinib 1larotrectinib 1fluoromisonidazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × neratinib × Thoracic × Clear all
NCT06519110 2024-07-25

CVL009-C2001

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
60 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Salivary Gland Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡